All News
Consequences of TNF inhibition (3.18.2022)
This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Is it really seronegative RA!!!!
Happening now. #RnI2022 @RheumNow https://t.co/R3UTYuZRvJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
“best laid plans of mice and men oft go astray”.
Dr. Cush giving his opening remarks and pod at #Rnl2022 https://t.co/o9lenN1Dkd
Dr. John Cush RheumNow ( View Tweet)
Welcome to #RNL2022 !
Not only are we in-person in Texas, we have people online from all over the US and Canada to New Zealand and Japan!
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is kicking off with a pod on Rheumatoid Arthritis - Future Improvements. Dr. Cush will lead the first presentation on Treatment Choices in Refractory RA. #RNL2022 https://t.co/H3RbDPZxM1
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is HERE. Welcome everyone! What pod are you looking forward to the most?
Anyone out there who is still on the fence--virtual registration is still open. Join us!
https://t.co/3wKgCKqvfD
#RNL2022 https://t.co/W2hUpZ2Y8N
Links:
Dr. John Cush RheumNow ( View Tweet)
Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis
Bronchiectasis in rheumatoid arthritis-associated (RA-BR) is uncommon, is unrelated to interstitial lung disease (ILD), but like ILD can substantially impact RA outcomes.
https://t.co/xm8HWJkI5C https://t.co/JztHlzGw65
Links:
Dr. John Cush RheumNow ( View Tweet)
Disappointment Behind Acute Gout Hospitalizations
https://t.co/Hd1g5Kvwwr https://t.co/jYFVVOQOZX
Links:
Dr. John Cush RheumNow ( View Tweet)
Environmental Pollutants Ups Autoimmune Disease Risk
An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, CTDs and inflammatory bowel diseases (IBD).
https://t.co/LVCn8zgdpG https://t.co/wzi2GzSmGY
Links:
Dr. John Cush RheumNow ( View Tweet)
Medscapes 2022 Physician Suicide report. Sadly 10% of MDs have considered suicide. Highest in pathology (13%), surgery (12%), oncology (12%), ID (11%), EM(11%). LOWEST in Rheumatology (5%), nephrology (2%) https://t.co/ER8kNfcPEh https://t.co/cWQobpIO97
Links:
Dr. John Cush RheumNow ( View Tweet)
Happy Match Day to all newly matched doctors! We can't wait to see who becomes a rheumatologist in a few years. Enjoy your residency and celebrate your amazing accomplishment today! https://t.co/Yuhu7ksmog
Dr. John Cush RheumNow ( View Tweet)
Among 98 women with axSpA, there were 335 pregnancies & 279 live births - 52% uncomplicated and 48% complicated (13%) multiple complications. axSpA had more Preterm birth (13 vs 5%), pre-eclampsia (7 vs 3%), Low birth Wt (8 vs 3%) https://t.co/i43HKduAgu https://t.co/XHbtH9YMrt
Links:
Dr. John Cush RheumNow ( View Tweet)
Baricitinib has been studied in 15 relapsing GCA pts - prospective, open-label, BARI 4 mg/d w/ GC taper. 14/15 completed 52 wks; 13/15 went into remission and d/c steroids. There was 1 Bari D/C for adverse event & 1 pt w/ serious AE. 1 pt relapsed. https://t.co/J5bjdPAFdm https://t.co/LsuSVP8L0R
Links:
Dr. John Cush RheumNow ( View Tweet)
Psoriasis RCT studied ADA+MTX (31) vs ADA (30); after 12 mos, a (non-significant) better drug survival w/ ADA-MTX (74 vs 59%; p=0.15). Also favoring, but not signif was PASI 75 (58 vs 37%). Fewer anti-ADA Abs seen w/ ADA-MTX (23 vs 60%; p<0.01) https://t.co/9CAQrpl6hU https://t.co/mr0ZaJ9mbW
Links:
Dr. John Cush RheumNow ( View Tweet)
Frailty: a decline in the physiologic reserve & function of several systems, leading to increased vulnerability and adverse health outcomes. Not just age; increased in RA (33%) more than AS or PsA. Frailty is dynamic & potentially reversible https://t.co/82hkGKoRxV https://t.co/7d9sycC6S2
Links:
Dr. John Cush RheumNow ( View Tweet)
Infants and children do get COVID; all races, 35% w/ comorbidities. CDC study from 99 counties in 14 US states shows betw 3/20 & 2/22 there were 2,637 hospitalized infants & children 0–4 yrs old; 24% went to ICU; there were 18 deaths https://t.co/mWyXAj2GbT https://t.co/MYN37JKziD
Links:
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced that the FDA has approved Rinvoq (upadacitinib) for use in adults with active ulcerative colitis (after failing TNFi); approval based on 3 endoscopic UC trials. Starting dose is 45 mg/d, then maintain w/ 15 mg (some can get 30 mg) https://t.co/ZUbnkR7LMY https://t.co/dE1JkxzkSz
Links:
Dr. John Cush RheumNow ( View Tweet)
Another Rx for #PsA #psoriaticarthritis Deucravacitinib is shown to be effective. Good news but this adds to the dilemma of what to use in PsA Rx and in what order. Rational Rx may need #personalized Rx for best bang for buck! https://t.co/JQs7BlQwos
Janet Pope Janetbirdope ( View Tweet)
Individualized Therapy in Ankylosing Spondylitis
Whether patients with AS would improve substantially with TNF inhibitor therapy was predicted with moderate to high accuracy based on a lab test and two measures of disease activity, researchers reported.
https://t.co/hbbYqTiWGE https://t.co/Hx2U4y2e0F
Links:
Dr. John Cush RheumNow ( View Tweet)
Intravenous (IV) form of tramadol (Schedule IV) went in front of the FDA Drug Safety & Risk and Anesthetic/Analgesic Advisory Committees yesterday. They voted 14-8 against approval of IV tramadol (now available as tabs, liquid) https://t.co/AP2G7w8z1h https://t.co/lr9aLJSKi6
Links:
Dr. John Cush RheumNow ( View Tweet)